ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-OR59

T Cell-Receptor (TCR)-Independent Activation of CD8 Effector T Cells by IL-15 and IFNβ Drives Kidney Damage in Lupus Nephritis

Session Information

Category: Pathology and Lab Medicine

  • 1800 Pathology and Lab Medicine

Authors

  • Skopnik, Christopher, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Metzke, Diana, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Freund, Paul, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Prskalo, Luka, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Grothgar, Emil, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Wagner, Leonie Felicitas, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Goerlich, Nina, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Bunse, Mario, Max-Delbruck-Centrum fur Molekulare Medizin in der Helmholtz-Gemeinschaft, Buch, Berlin, Germany
  • Hiepe, Falk, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Klocke, Jan, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
  • Enghard, Philipp, Charite Universitatsmedizin Berlin, Berlin, Berlin, Germany
Background

Lupus nephritis (LN) implies morbidity in Systemic Lupus Erythematosus (SLE). A T cell-rich infiltrate parallels deposition of antibodies. How infiltrating T cells contribute to kidney damage is unclear. They can also be observed in urine, which thus can be used as a “window into the kidney” to investigate the cellular pathogenesis of LN. We report analysis of kidney infiltrating T cells found in urine to test if a renal autoimmune reaction contributes to tubulointerstitial inflammation (TII).

Methods

Urinary T and tubular epithelial cells (TEC) were quantified by flow cytometry (FC) in LN patients. T cells were subjected to single cell RNA sequencing after FC sort from urine and blood of five LN patients at flare. Comparison of gene transcription revealed putatively pathogenic cells. 67 T cell receptors (TCR) from expanded clonotypes were cloned to test specificity; T cell subsets from blood were subjected to in-vitro experiments. T cell stimulating cytokines were determined in urine from LN and healthy donors, reflecting the renal milieu.

Results

Majority of urinary T cells in LN are of CD8 lineage, the amount of which correlates with urinary TEC, a proxy for kidney damage. Mainly being of effector memory phenotype they are recruited partially from a CX3CR1 positive subset in blood which has a of type I interferon (IFN) signature. TCR analysis revealed expanded CD8 clones, none of which reacted with autologous TEC (0/18). Reactivity to viral CMV and EBV epitopes was shown for 15/67 clones. CMV or EBV was not detectable in respective kidney biopsies. In kidney tissue and/or urine we detected elevated levels of T cell stimulating cytokines, like IL-15. In-vitro, stimulation of CD8 T cells with IL-15 and IFNβ caused TCR-independent activation, degranulation and secretion cytokines TNF and IFNγ, almost exclusively by CX3CR1 positive CD8 effector T cells.

Conclusion

Contribution of CD8 T cells to TII and TEC damage in LN is antigen and TCR independent. In-vivo stimulation with IL-15 and type I IFN may be sufficient to trigger effector functions of a CX3CR1 positive subset. Targeting these cells in the blood, their migration, their response to cytokines or reducing renal cytokine levels may prevent LN flares and represent a tailored treatment.